Thorinane
Enoxaparin sodium biosimilar developed by Pharmathen. Reference product Clexane (Lovenox in the United States).
Brands by market: Thorinane (EU, lapsed) · Commercial partner or holder: Pharmathen · Company profile
FDANot listed
EMAWithdrawn
MHRANot listed
PMDANot listed
HCNot listed
CDSCONot listed
EDENot listed
Not yet approved in any of the 7 markets
Connections
About Thorinane
Thorinane was Pharmathen's enoxaparin, approved in Europe a day before Inhixa in September 2016. Its licence lapsed in 2019 and it is no longer marketed.
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union · Thorinane
European Medicines Agency and European CommissionWithdrawnBrand
Thorinane
Holder or applicant
Pharmathen S.A.
Pathway
Centralised (Article 10(4))
Approved
Sep 2016
Application or permission
EMEA/H/C/003795
Withdrawn
Sep 2019
Presentations
see SmPC
Remarks
Authorisation lapsed 15 September 2019.
Source
S017 (EMA) · checked Sep 2026
MHRA
United Kingdom
Not listed by MHRA.
PMDA
Japan
Not listed by PMDA.
HC
Canada
Not listed by HC.
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Chronology
- EMASep 2019Thorinane authorisation withdrawn
Sources
S017EMA, medicines data table (medicines-output-medicines-report_en.xlsx) Primary (regulator)
Planning enoxaparin sodium biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.